Monopar Therapeutics Appoints Susan Rodriguez as Chief Commercial Officer

By Chris Stiles • Monday, March 02 10:49 • Permanent Link

Monopar Therapeutics Inc. has made a significant move in expanding its leadership team with the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer. This comes at a crucial time as the company prepares to submit a new drug application to the U.S. Food and Drug Administration in the first half of 2026 for its late-stage investigational therapy for Wilson disease, ALXN1840.

Rodriguez's appointment is a strategic decision, considering her extensive experience in the biopharmaceutical industry, spanning over 30 years. Her most recent role as Chief Operating Officer of Avadel Pharmaceuticals saw her playing a key role in the company's commercial strategy and execution, contributing to Avadel's acquisition by Alkermes for over $2 billion.

Her track record includes successfully guiding organizations through high-growth phases and establishing commercial capabilities for the successful launch and adoption of innovative rare disease therapies. Her experience in leading commercial teams will be invaluable as Monopar advances ALXN1840 toward approval.

Monopar's focus on Wilson disease is notable, as ALXN1840 represents a major advancement in the treatment of this condition, marking the first such development in decades. The company's commitment to broad patient access and maximizing the therapy's impact is evident in Rodriguez's appointment to lead the commercial strategy and infrastructure build-out.

It's worth noting that Monopar Therapeutics is a clinical-stage biopharmaceutical company with a late-stage ALXN1840 for Wilson disease, as well as radiopharmaceutical programs including Phase 1-stage MNPR-101-ZR for imaging advanced cancers, and Phase 1A-stage MNPR-101-LU and late preclinical-stage MNPR-101-AC for the treatment of advanced cancers. These programs indicate the company's diversified focus on addressing unmet medical needs across different therapeutic areas.

Following these announcements, the company's shares moved 1.35%, and are now trading at a price of $70.00. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.